Crossmark

Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial

Crossref DOI link: https://doi.org/10.1186/s12967-023-04213-4

Published Online: 2023-05-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oraee-Yazdani, Saeed

Tavanaei, Roozbeh

Rostami, Fatemeh

Hajarizadeh, Atieh

Mehrabadi, Marzieh

Akhlaghpasand, Mohammadhosein

Tamaddon, Mona

Khannejad, Samin

Yazdani, Kaveh Oraii

Zali, Alireza
License Information

Text and Data Mining valid from 2023-05-27

Version of Record valid from 2023-05-27
More Information

Article History

Received: 13 February 2023

Accepted: 19 May 2023

First Online: 27 May 2023

Declarations

:

: This investigation was approved by the institutional review board of the Shohada Tajrish hospital and the ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.REC.1396.224). This clinical trial was also registered at the Iranian Registry of Clinical Trials (IRCT20200502047277N2). Before enrollment, patients were fully informed regarding the experimental nature of the study intervention, all potential outcomes, and possible complications or intervention-related AEs. After that, written informed consent, including all the study procedures was obtained from all patients.

: Written informed consent for publication of individual data was obtained from all patients.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below